Literature DB >> 14593495

Clinical and genetic risk factors of herpes zoster in patients with systemic lupus erythematosus.

Tae-Young Kang1, Hye-Soon Lee, Tae-Hwan Kim, Jae-Bum Jun, Dae-Hyun Yoo.   

Abstract

OBJECTIVE: The aim of this study was to determine the clinical and genetic risk factors that influence herpes zoster occurrence in patients with systemic lupus erythematosus (SLE).
METHODS: Three hundred three SLE patients meeting the American College of Rheumatology criteria were enrolled in this study. Herpes zoster was diagnosed when classic grouped vesicles were noted. Medical records were reviewed retrospectively to collect clinical information. For Fc gamma receptor IIa (Fc gamma RIIa) and Fc gamma RIIIa genotyping, polymerase chain reaction (PCR) using allele-specific primers was performed. The PCR sequence-specific oligonucleotide probe method was utilized in human HLA-DRB1 genotyping.
RESULTS: Forty-two cases (13.9%) of zoster occurred among 303 SLE patients. The incidence of zoster in patients with SLE was 32.5/1,000 patients per year. Patients who developed zoster had higher rates of lupus nephritis (P = 0.018) and positive anti-Sm antibody (P = 0.019). However, Fc gamma RIIa and Fc gamma RIIIa polymorphism and the HLA-DRB1 genotype did not influence herpes zoster occurrence.
CONCLUSION: Systemic lupus erythematosus patients with lupus nephritis or anti-Sm antibody are at higher risk of herpes zoster. Fc gamma RIIa (H/R131), Fc gamma RIIIa (F/V176), and HLA-DRB1 genetic polymorphisms did not influence the occurrence of herpes zoster in these patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14593495     DOI: 10.1007/s00296-003-0403-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  28 in total

1.  Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function.

Authors:  J E Salmon; J C Edberg; N L Brogle; R P Kimberly
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

2.  Immune responses to varicella-zoster in the aged.

Authors:  B L Burke; R W Steele; O W Beard; J S Wood; T D Cain; D J Marmer
Journal:  Arch Intern Med       Date:  1982-02

Review 3.  Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus.

Authors:  T H Weller
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

4.  [Herpetic viral diseases and systemic lupus erythematosus].

Authors:  J Vachtenheim; J Grossmann
Journal:  Pol Tyg Lek       Date:  1965-12-06

5.  High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis.

Authors:  K Nagasawa; Y Yamauchi; Y Tada; T Kusaba; Y Niho; H Yoshikawa
Journal:  Ann Rheum Dis       Date:  1990-08       Impact factor: 19.103

6.  Herpes zoster in patients with systemic lupus erythematosus.

Authors:  H M Moutsopoulos; J D Gallagher; J L Decker; A D Steinberg
Journal:  Arthritis Rheum       Date:  1978 Sep-Oct

7.  Intrinsic human glomerular mesangial cells can express receptors for IgG complexes (hFc gamma RIII-A) and the associated Fc epsilon RI gamma-chain.

Authors:  H H Radeke; J E Gessner; P Uciechowski; H J Mägert; R E Schmidt; K Resch
Journal:  J Immunol       Date:  1994-08-01       Impact factor: 5.422

8.  The epidemiology of varicella and its complications.

Authors:  P W Choo; J G Donahue; J E Manson; R Platt
Journal:  J Infect Dis       Date:  1995-09       Impact factor: 5.226

9.  A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding.

Authors:  P A Warmerdam; J G van de Winkel; A Vlug; N A Westerdaal; P J Capel
Journal:  J Immunol       Date:  1991-08-15       Impact factor: 5.422

10.  A cloned major histocompatibility complex-restricted trinitrophenyl-reactive human helper T cell line that activates B cell subsets via two distinct pathways.

Authors:  M A Principato; G S Thompson; S M Friedman
Journal:  J Exp Med       Date:  1983-11-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

2.  Carbamazepine-Induced Stevens-Johnson Syndrome Sparing the Skin Previously Affected by Herpes Zoster Infection in a Patient with Systemic Lupus Erythematosus: A Reverse Isotopic Phenomenon.

Authors:  Daniela Tenea
Journal:  Case Rep Dermatol       Date:  2010-08-09

3.  Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort.

Authors:  Hsin-Hua Chen; Yi-Ming Chen; Tzeng-Ji Chen; Joung-Liang Lan; Ching-Heng Lin; Der-Yuan Chen
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

4.  Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.

Authors:  David Jayne; Brad Rovin; Eduardo F Mysler; Richard A Furie; Frederic A Houssiau; Teodora Trasieva; Jacob Knagenhjelm; Erik Schwetje; Yen Lin Chia; Raj Tummala; Catharina Lindholm
Journal:  Ann Rheum Dis       Date:  2022-02-10       Impact factor: 27.973

5.  Chloroquine diphosphate: a risk factor for herpes zoster in patients with dermatomyositis/polymyositis.

Authors:  Gilmara Franco da Cunha; Fernando Henrique Carlos de Souza; Maurício Levy-Neto; Samuel Katsuyuki Shinjo
Journal:  Clinics (Sao Paulo)       Date:  2013-05       Impact factor: 2.365

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.